Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide

Keyphrases

• Hypotensive Effect 100%
• Atrial Natriuretic Peptide 100%
• PEGylation 100%
• Fmoc 83%
• Blood Pressure Lowering 50%
• Antihypertensive Drugs 33%
• Physiological Condition 33%
• Wistar Rats 33%
• Natriuretic Peptides 33%
• Blood Pressure 16%
• Clinical Application 16%
• Incubation 16%
• Hypotension 16%
• Protein Drug 16%
• Natriuresis 16%
• Prodrug 16%
• Control Value 16%
• Low Blood Pressure 16%
• Amino Acid Side Chains 16%
• Active Peptide 16%
• Slow Release 16%
• Adrenaline 16%
• Lag Period 16%
• Vasodilation 16%
• Biological Half-life 16%
• Low Bioavailability 16%
• Bolus Administration 16%
• Chemical Hydrolysis 16%
• PEG Chain 16%
• PEGylated Prodrug 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Atrial Natriuretic Factor 100%
• PEGylation 100%
• Polyethylene Glycol 50%
• Antihypertensive Agent 33%
• Wistar Rat 33%
• Prodrug 33%
• Hypotension 33%
• Natriuretic Factor 33%
• Bioavailability 16%
• Epinephrine 16%
• Alanine 16%
• Biological Half-Life 16%